Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602), Lausanne

Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 3603), Geneva

Melanoma Institute Australia ( Site 3402), Wollstonecraft

Tasman Oncology Research Pty Ltd ( Site 3403), Southport

Fiona Stanley Hospital ( Site 3401), Murdoch

Universitaetsspital Zuerich ( Site 3601), Zuerich Flughafen

NYU Clinical Cancer Center ( Site 3002), New York

Hopital La Timone ( Site 3103), Marseille

University of Pennsylvania Abramson Cancer Center ( Site 3008), Philadelphia

Istituto Europeo di Oncologia ( Site 3301), Milan

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022), Baltimore

Inova Schar Cancer Institute ( Site 3011), Fairfax

Duke Cancer Institute ( Site 3005), Durham

Institut Claudius Regaud ( Site 3105), Toulouse

West Cancer Center - East Campus ( Site 3014), Germantown

Martha Morehouse Tower ( Site 3020), Columbus

Policlinico Le Scotte - A.O. Senese ( Site 3377), Siena

Centre Hospitalier Lyon Sud ( Site 3102), Pierre-Bénite

A.P.H. Paris, Hopital Saint Louis ( Site 3107), Paris

University of Colorado, Anschutz Cancer Pavilion ( Site 3012), Aurora

The Angeles Clinic and Research Institute ( Site 3009), Los Angeles

Providence Saint John's Health Center ( Site 3010), Santa Monica

Gustave Roussy ( Site 3101), Villejuif

Oregon Health & Science University ( Site 3013), Portland

HaEmek Medical Center ( Site 3703), Afula

Rambam Health Care Campus-Oncology ( Site 3704), Haifa

Rabin Medical Center-Oncology ( Site 3705), Petah Tikva

Chaim Sheba Medical Center ( Site 3701), Ramat Gan

Hadassah Ein Karem Jerusalem ( Site 3702), Jerusalem